Source: Radio New Zealand
AFP / Thom Leach / Science Photo Library
Pharmac says shortages in some ADHD drugs are expected to last throughout 2026.
Its Chief Medical Officer, Dr David Hughes, in a statement to told Nine to Noon, rising demand and manufacturing constraints meant supply remains unpredictable.
The drug option most affected is methylphenidate, used in branded treatments such as Ritalin,and Concerta.
Pharmac has funded a new brand of methylphenidate along with an alternative medication, Lisdexamfetamine.
ADHD New Zealand says clinicians have identified that children and adolescents need priority access to slow release methylphenidate and have suggested prescribing alternative medications for any newly diagnosed adults.
Wellington GP Dr Michael Buckley, who has a special interest in ADHD, is predicting even further demand for the medicines as more people are diagnosed.
Sign up for Ngā Pitopito Kōrero, a daily newsletter curated by our editors and delivered straight to your inbox every weekday.
– Published by EveningReport.nz and AsiaPacificReport.nz, see: MIL OSI in partnership with Radio New Zealand
